[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640674":3},{"organization":4,"outcomesModule":7,"designInfo":49,"detailedDescription":11,"studyPopulation":11,"armGroups":55,"interventions":61,"overallOfficials":11,"centralContacts":66,"locations":72,"responsibleParty":91,"collaborators":11,"id":93,"slug":11,"hasResults":94,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":11,"eligibilityCriteria":98,"healthyVolunteers":94,"sex":99,"minAge":100,"maxAge":101,"enrollmentInfo":102,"targetDuration":11,"studyType":105,"phases":106,"briefSummary":109,"conditions":110,"keywords":11,"overallStatus":112,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Beijing InnoCare Pharma Tech Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":11},[9,13,16,18],{"measure":10,"description":11,"timeFrame":12},"The types, severity, correlation with the investigational drug and incidence of adverse events and serious adverse events",null,"2 years",{"measure":14,"description":11,"timeFrame":15},"The types, severity and incidence of dose-limiting toxicity (DLT)","1 year",{"measure":17,"description":11,"timeFrame":15},"The Recommended Dose (RD) and\u002For Maximum Tolerated Dose (MTD)",{"measure":19,"description":11,"timeFrame":12},"Objective response rate (ORR) by researchers",[21,23,25,27,29,31,33,35,37,39,41,43,45,47],{"measure":22,"description":11,"timeFrame":15},"Maximum Plasma Concentration (Cmax)",{"measure":24,"description":11,"timeFrame":15},"Time to Maximum Plasma Concentration (Tmax)",{"measure":26,"description":11,"timeFrame":15},"Half-life (T1\u002F2)",{"measure":28,"description":11,"timeFrame":15},"Area under the concentration-time curve from zero time to infinity (AUC0-∞)",{"measure":30,"description":11,"timeFrame":15},"Area under the concentration-time curve from zero time to the last measurable concentration time point t (AUC0-t)",{"measure":32,"description":11,"timeFrame":15},"Apparent Clearance(CL\u002FF)",{"measure":34,"description":11,"timeFrame":15},"Terminal Apparent Volume of Distribution (Vz\u002FF)",{"measure":36,"description":11,"timeFrame":12},"The ORR evaluated by the researchers",{"measure":38,"description":11,"timeFrame":12},"The Disease Control Rate (DCR) evaluated by the researchers",{"measure":40,"description":11,"timeFrame":12},"The Duration of Response (DOR) evaluated by the researchers",{"measure":42,"description":11,"timeFrame":12},"The Progression-Free Survival (PFS) evaluated by the researchers",{"measure":44,"description":11,"timeFrame":12},"The Radiographic Progression-Free Survival (rPFS) evaluated by the researchers",{"measure":46,"description":11,"timeFrame":12},"The Overall Survival (OS) evaluated by the researchers",{"measure":48,"description":11,"timeFrame":15},"Number of participants with anti-drug antibodies (ADA) to ICP-B208",{"allocation":50,"interventionModel":51,"interventionModelDescription":11,"primaryPurpose":52,"observationalModel":11,"timePerspective":11,"maskingInfo":53},"NA","SEQUENTIAL","TREATMENT",{"masking":54,"maskingDescription":11,"whoMasked":11},"NONE",[56],{"label":57,"type":58,"description":11,"interventionNames":59},"ICP-B208","EXPERIMENTAL",[60],"Drug: ICP-B208",[62],{"type":63,"name":57,"description":64,"armGroupLabels":65,"otherNames":11},"DRUG","ICP-B208 will be administered by intravenous infusion every 3 weeks (Q3W) until disease progression (PD) or the occurrence of unacceptable toxicity or withdrawal from the study for other reasons (whichever occurs first).",[57],[67],{"name":68,"role":69,"phone":70,"phoneExt":11,"email":71},"Aixia Lu","CONTACT","010-66609745","CO_HGRAC@innocarepharma.com",[73],{"facility":74,"status":11,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":85,"contacts":86},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100000","China","CN",{"type":81,"coordinates":82},"Point",[83,84],116.39723,39.9075,{"lat":84,"lon":83},[87],{"name":88,"role":69,"phone":89,"phoneExt":11,"email":90},"Lin Shen, M.D.","010-88196561","doctorshenlin@sina.cn",{"type":92,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640674",false,"NCT07617493","Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","An Open, Multicenter, Phase I\u002FII Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials","Inclusion Criteria:\n\n1. 18 years old to 75 years old;\n2. Unresectable locally advanced or metastatic gastrointestinal tumors or other advanced solid tumors that have failed previous systemic treatment and have been confirmed by histopathology or cytology;\n3. The ECOG physical fitness score is 0 to 1 point.\n4. There is at least one measurable lesion;\n5. The organ function level must meet the prescribed standards;\n6. Effective contraceptive measures should be taken from the date of signing the informed consent form until at least 6 months after the use of the last dose of the study drug.\n7. Voluntarily enroll in the group and sign the informed consent form, and follow the trial treatment protocol and visit plan.\n\nExclusion Criteria:\n\n1. Other active malignant tumors occurred within 3 years before the first administration of the study drug;\n2. Received the anti-tumor treatment defined by the protocol within the time range before the first administration of the study drug specified in the protocol;\n3. Trial participants with unstable primary CNS tumors or CNS metastases;\n4. Uncontrollable or significant major cardiovascular diseases;\n5. Severe or uncontrollable systemic diseases; Or any unstable systemic disease;\n6. Active infection as defined in the plan;\n7. Have a history of severe allergic reactions to active pharmaceutical ingredients, non-active components in drugs or antibody drugs;\n8. Those who are known to have a history of alcohol abuse or drug abuse;\n9. Other circumstances that the researcher deems unsuitable for participation in this study.","ALL","18 Years","75 Years",{"count":103,"type":104},539,"ESTIMATED","INTERVENTIONAL",[107,108],"PHASE1","PHASE2","To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors",[111],"Advanced Solid Tumor","NOT_YET_RECRUITING","2026-05-24",{"date":115,"type":116},"2026-06-01","ACTUAL",{"date":118,"type":104},"2026-06",{"date":120,"type":104},"2031-06",{"name":5,"class":6},1]